NLSP
NLS Pharmaceutics AG [NLSP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NLSP Stock Summary
In the News
NLSP Financial details
Company Rating
-
Market Cap
5.92M
Income
-31.45M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-1.23
Quick Ratio
2.68
Current Ratio
2.75
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
3.7%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-31.03%
-
-
-
-
SMA20
-52.38%
SMA50
-61.54%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
-911%
ROC
-2.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.132-1.58
52W High
-
52W Low
-
RSI
16
Rel Volume
0.2
Avg Volume
569.25K
Volume
113.99K
Perf Week
-77.95%
Perf Month
-86.83%
Perf Quarter
-
Perf Half Y
-87.18%
-
-
-
-
Beta
-0.836
-
-
Volatility
3.83%, 5.29%
Prev Close
0%
Price
2.91
Change
-12.08%
Company Profile
- Volume Average 569.25K
- Market Capitalization 5.92M
- Employee 6
- CEO Mr. Alexander Zwyer M.B.A.
- Headquarters Zurich,CH
- IPO Date 2021-01-29
-
Website
https://nlspharma.com 
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
